|
1
|
Ottaviani G, Robert RS, Huh WW, Palla S
and Jaffe N: Sociooccupational and physical outcomes more than 20
years after the diagnosis of osteosarcoma in children and
adolescents: limb salvage versus amputation. Cancer. 119:3727–3736.
2013.PubMed/NCBI
|
|
2
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
|
|
3
|
Ta HT, Dass CR, Choong PF and Dunstan DE:
Osteosarcoma treatment: state of the art. Cancer Metastasis Rev.
28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chou AJ, Kleinerman ES, Krailo MD, et al:
Addition of muramyl tripeptide to chemotherapy for patients with
newly diagnosed metastatic osteosarcoma: a report from the
Children’s Oncology Group. Cancer. 115:5339–5348. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Grignani G, Palmerini E, Dileo P, et al: A
phase II trial of sorafenib in relapsed and unresectable high-grade
osteosarcoma after failure of standard multimodal therapy: an
Italian Sarcoma Group study. Ann Oncol. 23:508–516. 2012.
View Article : Google Scholar
|
|
6
|
Wilhelm SM, Carter C, Tang L, et al: BAY
43-9006 exhibits broad spectrum oral antitumor activity and targets
the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in
tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu L, Cao Y, Chen C, et al: Sorafenib
blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and
induces tumor cell apoptosis in hepatocellular carcinoma model
PLC/PRF/5. Cancer Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mei J, Zhu X and Wang Z and Wang Z: VEGFR,
RET, and RAF/MEK/ERK pathway take part in the inhibition of
osteosarcoma Mg63 cells with sorafenib treatment. Cell Biochem
Biophys. 69:151–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Almhanna K and Philip PA: Safety and
efficacy of sorafenib in the treatment of hepatocellular carcinoma.
Onco Targets Ther. 2:261–267. 2009.PubMed/NCBI
|
|
10
|
Strumberg D, Clark JW, Awada A, et al:
Safety, pharmacokinetics, and preliminary antitumor activity of
sorafenib: a review of four phase I trials in patients with
advanced refractory solid tumors. Oncologist. 12:426–437. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lacouture ME, Reilly LM, Gerami P and
Guitart J: Hand foot skin reaction in cancer patients treated with
the multikinase inhibitors sorafenib and sunitinib. Ann Oncol.
19:1955–1961. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang H, Li Z and Wang K: Combining
sorafenib with celecoxib synergistically inhibits tumor growth of
non-small cell lung cancer cells in vitro and in vivo. Oncol Rep.
31:1954–1960. 2014.PubMed/NCBI
|
|
13
|
Morisaki T, Umebayashi M, Kiyota A, et al:
Combining celecoxib with sorafenib synergistically inhibits
hepatocellular carcinoma cells in vitro. Anticancer Res.
33:1387–1395. 2013.PubMed/NCBI
|
|
14
|
Pignochino Y, Dell’Aglio C, Basirico M, et
al: The combination of sorafenib and everolimus abrogates mTORC1
and mTORC2 upregulation in osteosarcoma preclinical models. Clin
Cancer Res. 19:2117–2131. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma JJ, Chen BL and Xin XY: XIAP gene
downregulation by small interfering RNA inhibits proliferation,
induces apoptosis, and reverses the cisplatin resistance of ovarian
carcinoma. Eur J Obstet gynecol Reprod Biol. 146:222–226. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheng JQ, Jiang X, Fraser M, et al: Role
of X-linked inhibitor of apoptosis protein in chemoresistance in
ovarian cancer: possible involvement of the phosphoinositide-3
kinase/Akt pathway. Drug Resist Updat. 5:131–146. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Holt SV, Brookes KE, Dive C and Makin GW:
Downregulation of XIAP by AEG35156 in paediatric tumor cells
induces apoptosis and sensitises cells to cytotoxic agents. Oncol
Rep. 25:1177–1181. 2011.PubMed/NCBI
|
|
18
|
Tao C, Lin H and Chen S: The regulation of
ERK and p-ERK expression by cisplatin and sorafenib in gastric
cancer cells. Gene. 552:106–115. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yuan JM, Li XD, Liu ZY, et al: Cisplatin
induces apoptosis via upregulating Wrap53 in U-2OS osteosarcoma
cells. Asian Pac J Cancer Prev. 12:3465–3469. 2011.PubMed/NCBI
|
|
20
|
Abe S, Nishimoto Y, Isu K, Ishii T and
Goto T: Japanese Musculoskeletal Oncology Group: Preoperative
cisplatin for initial treatment of limb osteosarcoma: its local
effect and impact on prognosis. Cancer Chemother Pharmacol.
50:320–324. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Anninga JK, Gelderblom H, Fiocco M, et al:
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we
stand? Eur J Cancer. 47:2431–2445. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao JG, Ren KM and Tang J: Overcoming
5-Fu resistance in human non-small cell lung cancer cells by the
combination of 5-Fu and cisplatin through the inhibition of glucose
metabolism. Tumour Biol. 35:12305–12315. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Murakami M, Zhao S, Zhao Y, et al:
Increased intratumoral fluorothymidine uptake levels following
multikinase inhibitor sorafenib treatment in a human renal cell
carcinoma xenograft model. Oncol Lett. 6:667–672. 2013.PubMed/NCBI
|
|
24
|
Gollob JA, Wilhelm S, Carter C and Kelley
SL: Role of Raf kinase in cancer: therapeutic potential of
targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol.
33:392–406. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Walter I, Wolfesberger B, Miller I, et al:
Human osteosarcoma cells respond to sorafenib chemotherapy by
downregulation of the tumor progression factors S100A4, CXCR4 and
the oncogene FOS. Oncol Rep. 31:1147–1156. 2014.PubMed/NCBI
|
|
26
|
Ullah MF: Cancer multidrug resistance
(MDR): a major impediment to effective chemotherapy. Asian Pac J
Cancer Prev. 9:1–6. 2008.PubMed/NCBI
|
|
27
|
Meyers PA, Schwartz CL, Krailo M, et al:
Osteosarcoma: a randomized, prospective trial of the addition of
ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and
high-dose methotrexate. J Clin Oncol. 23:2004–2011. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bruheim S, Xi Y, Ju J and Fodstad O: Gene
expression profiles classify human osteosarcoma xenografts
according to sensitivity to doxorubicin, cisplatin, and ifosfamide.
Clin Cancer Res. 15:7161–7169. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu WX, Tang LN, Lin F, Yao Y and Shen Z:
Comparison of pemetrexed plus cisplatin with gemcitabine plus
docetaxel in refractory/metastatic osteosarcoma: clinical outcomes
from a retrospective database monitored in a single institute.
Oncol Lett. 8:2243–2248. 2014.PubMed/NCBI
|
|
30
|
Lin F, Wang Q, Yu W, et al: Clinical
analysis of Chinese limb osteosarcoma patients treated by two
combinations of methotrexate, cisplatin, doxorubicin and
ifosfamide. Asia Pac J Clin Oncol. 7:270–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wei Y, Shen N, Wang Z, et al: Sorafenib
sensitizes hepatocellular carcinoma cell to cisplatin via
suppression of Wnt/β-catenin signaling. Mol Cell Biochem.
381:139–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Martinez-Lopez N, Athonvarangkul D,
Mishall P, Sahu S and Singh R: Autophagy proteins regulate ERK
phosphorylation. Nat Commun. 4:27992013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hayakawa J, Ohmichi M, Kurachi H, et al:
Inhibition of extracellular signal-regulated protein kinase or
c-Jun N-terminal protein kinase cascade, differentially activated
by cisplatin, sensitizes human ovarian cancer cell line. J Biol
Chem. 274:31648–31654. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mandic A, Viktorsson K, Heiden T, Hansson
J and Shoshan MC: The MEK1 inhibitor PD98059 sensitizes C8161
melanoma cells to cisplatin-induced apoptosis. Melanoma Res.
11:11–19. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Eicher C, Dewerth A, Thomale J, et al:
Effect of sorafenib combined with cytostatic agents on
hepatoblastoma cell lines and xenografts. Br J Cancer. 108:334–341.
2013. View Article : Google Scholar :
|
|
36
|
Wang X, Martindale JL and Holbrook NJ:
Requirement for ERK activation in cisplatin-induced apoptosis. J
Biol Chem. 275:39435–39443. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK
and Cheng AL: Increase of the resistance of human cervical
carcinoma cells to cisplatin by inhibition of the MEK to ERK
signaling pathway partly via enhancement of anticancer drug-induced
NF kappa B activation. Biochem Pharmacol. 63:142–1430. 2002.
View Article : Google Scholar
|
|
38
|
Woessmann W, Chen X and Borkhardt A:
Ras-mediated activation of ERK by cisplatin induces cell death
independently of p53 in osteosarcoma and neuroblastoma cell lines.
Cancer Chemother Pharmacol. 50:397–404. 2002. View Article : Google Scholar : PubMed/NCBI
|
